GLP-1 Cost & Access Center

Ozempic's list price is around $1,000 a month, and that number is what most people see first. It is also the number almost nobody pays. If your plan covers Ozempic for type 2 diabetes, you pay a formulary copay — commonly $25 to $60 a month once a manufacturer savings card is applied.

Where Ozempic differs from the newer weight-management drugs is cash pay. Novo Nordisk runs lower-cost self-pay vial programs for Wegovy, and Lilly does the same for Zepbound and Mounjaro, but there is no equivalent low-cost vial route for Ozempic. Uninsured, you are realistically looking at roughly $900 a month with a pharmacy coupon.

Coverage turns on one question more than any other: is the drug being used on-label? Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy and Zepbound are approved for chronic weight management. Ask a plan to cover a diabetes drug for weight loss and you have described the single most common denial in this category.

For weight-management coverage, plans typically want a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, prediabetes or sleep apnea. Nearly every GLP-1 prescription also needs prior authorization, and incomplete paperwork — not medical ineligibility — is the usual reason a first submission comes back denied.

Medicare is the notable hard stop. Part D is barred by statute from covering a drug used only for weight loss, though it can cover a GLP-1 for diabetes or another approved indication such as cardiovascular risk reduction. Medicaid varies by state, and commercial and employer plans vary by employer and plan year.

A manufacturer savings card is the largest single lever most insured people have, and it is free. Enrolled through NovoCare (Ozempic, Wegovy, Rybelsus) or LillyDirect (Mounjaro, Zepbound), it applies at the pharmacy counter and commonly brings a covered copay down to about $25 a month.

Three rules decide whether it helps you:

• Commercial and employer plans only. Federal law prohibits manufacturer copay assistance on Medicare, Medicaid or any other government program.
• There are caps. Most cards carry a monthly maximum and an annual maximum; once you hit the annual cap your cost can rise until the plan year resets.
• Enroll immediately. Sign up the day you're prescribed — the card does nothing retroactively for prescriptions you have already paid full price for.

Employer plans have become the most variable part of GLP-1 access. Many large employers added a weight-management benefit in recent years; others explicitly carved GLP-1s out of the formulary when costs rose. Two people at the same salary in the same city can face a $25 copay and a flat denial purely because of who they work for.

Because the decision sits with the employer rather than the insurer, the fastest route is usually not the pharmacy — it is HR or your benefits portal. Worth asking specifically:

• Does the plan cover GLP-1s for weight management, or only for type 2 diabetes?
• Is there a separate weight-management program or vendor you must enroll in first?
• Which GLP-1 is the plan-preferred one? The preferred drug carries the lowest copay.
• Is there a step-therapy requirement — do you have to try something cheaper first?
• Does the benefit change at the next plan year?

Re-check each plan year. Formularies, prior-authorization criteria and savings caps are reset annually, and a drug that was excluded last year is sometimes covered this year.

If you have no coverage, ignore the list price — it is not the number that applies to you. The manufacturers now run direct self-pay programs that price vials far below the pen list price: roughly $499 a month for Wegovy and Zepbound and about $549 for Mounjaro. These are the lowest-cost legitimate routes for most uninsured people seeking weight management.

Ozempic and Rybelsus have no comparable program. Cash prices there stay near $900 a month even with a pharmacy coupon such as GoodRx, which is why an uninsured person whose goal is weight loss is almost always better served by an obesity-approved drug.

Compounded semaglutide and tirzepatide are often cheaper still, but availability and legality tightened considerably once the brand shortages resolved. Quality, dosing accuracy and sourcing vary, so treat it as a conversation to have with your prescriber rather than a straightforward discount.